Cellular response of a novel PLK inhibitor in breast cancer cells
Zhi Hu(Oregon Health & Science University), Joe W. Gray(University of Newcastle Australia), Heidi S. Feiler(Oregon Health & Science University), Richard Wooster(GlaxoSmithKline (United States)), Sylvie Laquerre(Johnson & Johnson (United States)), Debopriya Das(Lawrence Berkeley National Laboratory), Shenda Gu, Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Jeffrey J. Jackson(Rapt Therapeutics (United States)), Barbara L. Weber, Wen‐Lin Kuo(Lawrence Berkeley National Laboratory), Nicholas Wang(Oregon Health & Science University)
Cancer Research
May 1, 2008
Cited by 0
Related Papers
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|602
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition
|Clinical Cancer Research|2011|600
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
|Journal of Clinical Investigation|2012|591